Screening system to identify 5 alpha reductase inhibitors

Funding Agency:
Unilever

Benign Prostatic Hyperplasia (BHP) is a common condition affecting older men in which the prostate gland becomes enlarged, which could cause issues associated with urination. Androgenetic Alopecia (AGA) is the most common form of hair loss. Both diseases are mediated by androgens. 

The main pathogenic androgen in those conditions (BHP and AGA) is dihydrotestosterone (DHT). DHT is a product of the conversion of testosterone by the enzyme 5-ɑ reductase (5AR). 

There are two key isoforms of the 5-a reductase (5AR) enzyme, Type I and Type II. These are encoded by different genes. Understanding the variations in tissue distribution and functionality between these isoforms (Type I and Type II) is crucial for the development of targeted interventions for DHT regulation. 

Our goal is to reduce DHT levels in targeted biological systems. This reduction can be achieved through various mechanisms, such as enzyme inhibition, a decrease in enzyme activity, or modulation of gene expression. Novel inhibitors have the potential to contribute to the development of therapies for conditions like BPH and AGA by targeting the overproduction of DHT. 

We are seeking tools and screening capabilities (ideally high throughput in nature) to screen novel substances for their potential to inhibit 5-alpha reductase.

Deadline: Dec. 31, 2023

Agency Website

Amount Description

Funding is proposal dependent, but an accepted proposal could expect support in the range of 25,000 - 100,000 USD (milestone dependent) with the potential for follow on funding.

Funding Type

Grant

Eligibility

Faculty

Category

Engineering and Physical Sciences
Environmental & Life Sciences
Medical
Medical - Basic Science

External Deadline

December 31, 2023